INOVIO PHARMACEUTICALS, INC.

Inovio Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and commercializes DNA medicines. These medicines are designed to treat and protect people from diseases linked to human papillomavirus (HPV), various cancers, and infectious diseases. The company's DNA medicines platform utilizes SynCon technology to engineer specific plasmid DNA plasmids, along with CELLECTRA smart devices for delivering these DNA plasmids. Inovio's primary product candidate is INO-3107, which is in a Phase 1/2 trial for HPV-related recurrent respiratory papillomatosis. Other products in its development pipeline include VGX-3100 for HPV-related cervical high-grade squamous intraepithelial lesions, INO-3112 for HPV-related Oropharyngeal squamous cell carcinoma (currently in a Phase 2 trial), and INO-5401 for glioblastoma multiforme (also in a Phase 2 trial). Additionally, the pipeline features INO-4201 for Ebola Virus Disease (in a Phase 1b trial), INO-4800 for COVID-19 (in a Phase 2/3 trial), and INO-6160 for human immunodeficiency virus (in a Phase 1 trial). The company collaborates with various partners, including ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. Inovio Pharmaceuticals, Inc. was founded in 1983 and is based in Plymouth Meeting, Pennsylvania.